Poster Presentations

Title / Author Description Link / File
Leishman, A., Leonard, H., Poynton, F., et al. First-in-class inhibitors of ERAP1 have the potential to be a transformative immunotherapy in oncology. Poster exhibited at AACR 2021 (9-14 Apr, 2021). Request Poster
Leishman A., Poynton F., Ternette N., et al. Immunopeptidome changes mediated by a novel ERAP1 inhibitor leads to tumor growth inhibition. Poster exhibited at SITC 2020 (11-14 Nov, 2020). Request Poster
Leonard, H., Remtulla, A., Poynton, F., et al. Potent oral ERAP1 inhibitors modify the immunopeptidome in vivo and are novel immunotherapy agents. Poster exhibited at AACR 2020 (24-29 Apr, 2020). Request Poster
Young, L., Ware, J., McIntyre, P., et al Potent ERAP1 inhibitors modify the immunopeptidome and generate novel neoantigens. Poster exhibited at SITC 2019 (7-10 Nov, 2019). Request Poster

Relevant Publications

Title / Author Description Link / File
Wellcome Trust Case Control Consortium & The Australo-Anglo-American Spondylitis Consortium (TASC) Nat. Genet. 39, 1329-1337 (2007). View Paper
Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat. Genet. 42, 985–990 (2010). View Paper
James, E., Bailey, I., Sugiyarto G., et al. Induction of protective antitumor immunity through attenuation of ERAAP function. J Immunol. 190, 5839–46 (2013). View Paper
Cifaldi, L., Monaco, E.L., Forloni, M., et al. Natural Killer Cells Efficiently Reject Lymphoma Silenced for the Endoplasmic Reticulum Aminopeptidase Associated with Antigen Processing. Cancer Res. 71(5), 1597–606 (2010). View Paper
Manguso, R.T., Pope, H.W., Zimmer, M.D., et al. Nature. 547, 413–418 (2017). View Paper
Garrido, G., Schrand, B., Rabasa, A., et al. Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity. Nat Commun 10, 3773 (2019). View Paper
Zervoudi, E. Saridakis, E., Birtley, J.R. et al. Rationally designed inhibitor targeting antigen trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses. PNAS. 110(49), 19890–19895 (2013). View Paper
York, I.A., Chang, S., Saric, T., et al. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8–9 residues. Nat Immunol. 3(12), 1177-1184 (2002). View Paper
Nagarajan, N.A., Gonzalez, F. & Shasttri, N. Nonclassical MHC Class Ib-restricted Cytotoxic T Cells Monitor Antigen Processing in the Endoplasmic Reticulum. Nat Immunol. 13(6), 579-86 (2012). View Paper
Mpakali, A., Stratikos, E. The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy. Cancers. 13(1), 134. (2021). View Paper
Blanchard, N., Kanaseki, T., Escobar, H., et al. Endoplasmic Reticulum Aminopeptidase Associated with Antigen Processing Defines the Composition and Structure of MHC Class I Peptide Repertoire in Normal and Virus-Infected Cells. J Immunol. 184, 3033-3042 (2010). View Paper
Cifaldi, L., Romania, P., Falco, M. et al. ERAP1 regulates natural killer cell function by controlling the engagement of inhibitory receptors. Cancer Res. 75(5), 824-34 (2015). View Paper